Liability risks for executives are increasing significantly: New regulatory requirements such as NIS-2, CSRD, and the Supply Chain Act are expanding the responsibilities of managing
KPMG Law Rechtsanwaltsgesellschaft mbH and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) advised Brain Biotech AG on the monetization of licensing rights with Royalty Pharma and the conclusion of an exclusive pharmaceutical licensing agreement for the G-dase-E®-CRISPR-Cas technology with Akribion Therapeutics.
BRAIN Biotech has entered into an agreement with Royalty Pharma for the monetization of the license rights to the investigational pharmaceutical compound deucrictibant in the amount of up to EUR 128.88 million. BRAIN Biotech will receive an upfront payment of EUR 18.41 million, additional potential regulatory milestone payments of up to EUR 18.42 million and additional potential long-term sales-related milestones of up to EUR 92.05 million.
In addition, BRAIN Biotech has entered into an exclusive technology license agreement with Akribion Therapeutics GmbH for the use of the genome editing nuclease G-dase E® in the pharmaceutical field. BRAIN Biotech will receive up to EUR 92.3 million in R&D and commercial milestone payments from Akribion for the granting of these exclusive rights for use in the pharmaceutical field. In addition, BRAIN Biotech will be entitled to royalties from future net sales. The payment structure is based on progress in clinical development and future commercialization success.
KPMG Law provided comprehensive legal advice on the structuring of the transaction, including all aspects of copyright, licensing and transaction law.
The accounting and tax advice as well as the comprehensive valuation of the licenses was provided by a team from KPMG.
Royalty Pharma was advised by an international team from Goodwin Procter.
Advisor Brain Biotech AG:
KPMG Law Rechtsanwaltsgesellschaft mbH: Stefan Kimmel (Partner, Corporate/M&A, Berlin), Dr. Anna Wipper (Partner, IP/IT, Berlin) – both lead – Gunars Urdze (Senior Manager, Corporate, M&A, Cologne), Dr. Thomas Beyer (Senior Manager, IP/IT, Berlin), Isabelle Knoché (Senior Manager, Legal Financial Services, Frankfurt/Main), Christina Laux (Senior Associate , Legal Financial Services, Frankfurt/Main),; Dr. Jonas Brueckner (Partner, Antitrust and Foreign Trade Law, Berlin).
KPMG AG Wirtschaftsprüfungsgesellschaft: Christian Klingbeil (Partner, Valuation, Head of Deal Advisory Life Science, Munich), Sebastian Bongartz (Senior Manager, International Transaction Tax, Düsseldorf).
KPMG Law
© 2026 KPMG Law Rechtsanwaltsgesellschaft mbH, associated with KPMG AG Wirtschaftsprüfungsgesellschaft, a public limited company under German law and a member of the global KPMG organisation of independent member firms affiliated with KPMG International Limited, a Private English Company Limited by Guarantee. All rights reserved. For more details on the structure of KPMG’s global organisation, please visit https://home.kpmg/governance.
KPMG International does not provide services to clients. No member firm is authorised to bind or contract KPMG International or any other member firm to any third party, just as KPMG International is not authorised to bind or contract any other member firm.
